Inappropriate Use of Combined Hormonal Contraceptives for Birth Control Among Women of Reproductive Age in the United States

2013 ◽  
Vol 22 (7) ◽  
pp. 595-603 ◽  
Author(s):  
Jingbo Yu ◽  
X. Henry Hu
Keyword(s):  
United States ◽  
Birth Control ◽  
The United States ◽  
Reproductive Age ◽  
Hormonal Contraceptives ◽  
Women Of Reproductive Age ◽  
Inappropriate Use ◽  
Combined Hormonal Contraceptives

scholarly journals Cigar and Marijuana Blunt Use Among Pregnant and Nonpregnant Women of Reproductive Age in the United States, 2006–2016

2018 ◽  
Vol 108 (8) ◽  
pp. 1073-1075 ◽  
Author(s):  
Victoria H. Coleman-Cowger ◽  
Wallace B. Pickworth ◽  
Robert A. Lordo ◽  
Erica N. Peters
Keyword(s):  
United States ◽  
The United States ◽  
Reproductive Age ◽  
Women Of Reproductive Age

scholarly journals Association between contemporary hormonal contraception and ovarian cancer in women of reproductive age in Denmark: prospective, nationwide cohort study

BMJ ◽  
2018 ◽  
pp. k3609 ◽  
Author(s):  
Lisa Iversen ◽  
Shona Fielding ◽  
Øjvind Lidegaard ◽  
Lina S Mørch ◽  
Charlotte W Skovlund ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Relative Risk ◽  
Hormonal Contraception ◽  
Reproductive Age ◽  
Hormonal Contraceptives ◽  
Ovarian Cancer Risk ◽  
Women Of Reproductive Age ◽  
Ovarian Cancers ◽  
Study Population ◽  
Combined Hormonal Contraceptives

AbstractObjectivesTo investigate the association between contemporary combined hormonal contraceptives (including progestogen types in combined preparations and all progestogen-only products) and overall and specific types of ovarian cancer.DesignProspective, nationwide cohort study.SettingDenmark, 1995-2014.ParticipantsAll women aged 15-49 years during 1995-2014 were eligible. Women were excluded if they immigrated after 1995, had cancer (except non-melanoma skin cancer), had venous thrombosis, or were treated for infertility before entry (final study population included 1 879 227 women). Women were categorised as never users (no record of being dispensed hormonal contraception), current or recent users (≤1 year after stopping use), or former users (>1 year after stopping use) of different hormonal contraceptives.Main outcome measuresPoisson regression was used to calculate relative risk of ovarian cancer among users of any contemporary combined hormonal contraceptives and by progestogen type in combined preparations and all progestogen-only products, including non-oral preparations. Separate analyses examined women followed up to their first contraception type switch and those with full contraceptive histories. Duration, time since last use, and tumour histology were examined and the population prevented fraction were calculated.ResultsDuring 21.4 million person years, 1249 incident ovarian cancers occurred. Among ever users of hormonal contraception, 478 ovarian cancers were recorded over 13 344 531 person years. Never users had 771 ovarian cancers during 8 150 250 person years. Compared with never users, reduced risks of ovarian cancer occurred with current or recent use and former use of any hormonal contraception (relative risk 0.58 (95% confidence interval 0.49 to 0.68) and 0.77 (0.66 to 0.91), respectively). Relative risks among current or recent users decreased with increasing duration (from 0.82 (0.59 to 1.12) with ≤1 year use to 0.26 (0.16 to 0.43) with >10 years’ use; P<0.001 for trend). Similar results were achieved among women followed up to their first switch in contraceptive type. Little evidence of major differences in risk estimates by tumour type or progestogen content of combined oral contraceptives was seen. Use of progestogen-only products were not associated with ovarian cancer risk. Among ever users of hormonal contraception, the reduction in the age standardised absolute rate of ovarian cancer was 3.2 per 100 000 person years. Based on the relative risk for the never use versus ever use categories of hormonal contraception (0.66), the population prevented fraction was estimated to be 21%—that is, use of hormonal contraception prevented 21% of ovarian cancers in the study population.ConclusionsUse of contemporary combined hormonal contraceptives is associated with a reduction in ovarian cancer risk in women of reproductive age—an effect related to duration of use, which diminishes after stopping use. These data suggest no protective effect from progestogen-only products.

scholarly journals Trends and associated characteristics for Chagas disease among women of reproductive age in the United States, 2002 to 2017

2020 ◽  
Vol 11 ◽  
pp. e00167
Author(s):  
Chioma Ikedionwu ◽  
Deepa Dongarwar ◽  
Manvir Kaur ◽  
Lisa Nunez ◽  
Annabella Awazi ◽  
...  
Keyword(s):  
United States ◽  
Chagas Disease ◽  
The United States ◽  
Reproductive Age ◽  
Women Of Reproductive Age

Vaginal and rectal clostridial colonization among women of reproductive age in the United States

Contraception ◽  
2010 ◽  
Vol 82 (2) ◽  
pp. 214 ◽  
Author(s):  
C. Shannon ◽  
M. Veatch ◽  
E. Chong ◽  
K. Agnew ◽  
D. Nucatola ◽  
...  
Keyword(s):  
United States ◽  
The United States ◽  
Reproductive Age ◽  
Women Of Reproductive Age

scholarly journals Trends and Risk Factors for Leishmaniasis among Reproductive Aged Women in the United States

2021 ◽  
Vol 10 (2) ◽  
pp. 166-173
Author(s):  
Chioma Ikedionwu ◽  
Deepa Dongarwar ◽  
Courtney Williams ◽  
Evelyn Odeh ◽  
Maylis Nkeng Peh ◽  
...  
Keyword(s):  
United States ◽  
Risk Factors ◽  
Global Health ◽  
Protective Factor ◽  
Private Insurance ◽  
The United States ◽  
Reproductive Age ◽  
Women Of Reproductive Age ◽  
The Us ◽  
Clinical Awareness

Background and Objective: Leishmaniasis, a neglected tropical disease, is endemic in several regions globally, but commonly regarded as a disease of travelers in the United States (US). The literature on leishmaniasis among hospitalized women in the US is very limited. The aim of this study was to explore trends and risk factors for leishmaniasis among hospitalized women of reproductive age within the US. Methods: We analyzed hospital admissions data from the 2002-2017 Nationwide Inpatient Sample among women aged 15-49 years. We conducted descriptive statistics and bivariate analyses for factors associated with leishmaniasis. Utilizing logistic regression, we assessed the association between sociodemographic and hospital characteristics with leishmaniasis disease among hospitalized women of reproductive age in the US. Joinpoint regression was used to examine trends over time. Results: We analyzed 131,529,239 hospitalizations; among these, 207 cases of leishmaniasis hospitalizations were identified, equivalent to an overall prevalence of 1.57 cases per million during the study period. The prevalence of leishmaniasis was greatest among older women of reproductive age (35-49 years), Hispanics, those with Medicare, and inpatient stay in large teaching hospitals in the Northeast of the US. Hispanic women experienced a statistically significant increased odds of leishmaniasis diagnosis (OR, 1.80; 95% CI, 1.19-4.06), compared to Non-Hispanic (NH) White women. Medicaid and Private Insurance appeared to serve as a protective factor in both unadjusted and adjusted models. We did not observe a statistically significant change in leishmaniasis rates over the study period. Conclusion and Global Health Implications: Although the prevalence of leishmaniasis among women of reproductive age appears to be low in the US, some risk remains. Thus, appropriate educational, public health and policy initiatives are needed to increase clinical awareness and timely diagnosis/treatment of the disease.   Copyright © 2021 Ikedionwu, et al. Published by Global Health and Education Projects, Inc. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY 4.0) which permits unrestricted use, distribution, and reproduction in any medium, provided the original work, first published in this journal, is properly cited.

Sign in / Sign up

Export Citation Format

Share Document